Matches in Wikidata for { <http://www.wikidata.org/entity/Q93155465> ?p ?o ?g. }
Showing items 1 to 51 of
51
with 100 items per page.
- Q93155465 description "artículu científicu espublizáu en mayu de 2019" @default.
- Q93155465 description "scientific article published on 02 May 2019" @default.
- Q93155465 description "wetenschappelijk artikel" @default.
- Q93155465 description "наукова стаття, опублікована 2 травня 2019" @default.
- Q93155465 name "Chronic tyrosine kinase inhibitor (TKI) use in metastatic renal cell carcinoma (mRCC): can this lead to the adverse effect of hypogonadism?" @default.
- Q93155465 name "Chronic tyrosine kinase inhibitor (TKI) use in metastatic renal cell carcinoma (mRCC): can this lead to the adverse effect of hypogonadism?" @default.
- Q93155465 type Item @default.
- Q93155465 label "Chronic tyrosine kinase inhibitor (TKI) use in metastatic renal cell carcinoma (mRCC): can this lead to the adverse effect of hypogonadism?" @default.
- Q93155465 label "Chronic tyrosine kinase inhibitor (TKI) use in metastatic renal cell carcinoma (mRCC): can this lead to the adverse effect of hypogonadism?" @default.
- Q93155465 prefLabel "Chronic tyrosine kinase inhibitor (TKI) use in metastatic renal cell carcinoma (mRCC): can this lead to the adverse effect of hypogonadism?" @default.
- Q93155465 prefLabel "Chronic tyrosine kinase inhibitor (TKI) use in metastatic renal cell carcinoma (mRCC): can this lead to the adverse effect of hypogonadism?" @default.
- Q93155465 P1433 Q93155465-EF5682C3-B7E1-4971-96FE-DD37A2EF4DAF @default.
- Q93155465 P1476 Q93155465-4A33530D-E013-473C-A534-5B4748ACC28F @default.
- Q93155465 P2093 Q93155465-44724CEC-E117-47FB-8D4C-9E1051E0F1F5 @default.
- Q93155465 P2093 Q93155465-53B3BCBA-C515-42ED-A874-18665A4D3530 @default.
- Q93155465 P2093 Q93155465-63785C27-7F8E-4443-BCFC-7F58BD299D43 @default.
- Q93155465 P2093 Q93155465-73B06C5B-C4CB-4221-A46C-B09E1DDB7A0F @default.
- Q93155465 P2093 Q93155465-A5160393-6808-4530-89C0-37A691820DCA @default.
- Q93155465 P2093 Q93155465-B54AD069-73F5-4827-9377-75C0D1F9F75A @default.
- Q93155465 P2093 Q93155465-E7DBD903-6ABF-4AB5-94BB-48E993880BB0 @default.
- Q93155465 P304 Q93155465-AF04762B-ACD0-4F59-9312-84B68D095596 @default.
- Q93155465 P31 Q93155465-2EAA69F5-74E9-4398-B21C-D0CB430AA2DC @default.
- Q93155465 P356 Q93155465-F5159AEB-7A83-4C75-B58B-F9F108B18A2C @default.
- Q93155465 P433 Q93155465-3B696537-F994-4045-AF25-7AF945924C54 @default.
- Q93155465 P478 Q93155465-93BC2831-2CC3-41AF-8A01-988FC118CA46 @default.
- Q93155465 P577 Q93155465-613082A7-E5B3-4C71-9DEE-078B8537C84A @default.
- Q93155465 P698 Q93155465-F209C7CB-7DA6-43BE-8195-6BE11D54E344 @default.
- Q93155465 P921 Q93155465-B97B617A-E04B-4CDD-9D9C-6084DBB5650B @default.
- Q93155465 P921 Q93155465-D89D6733-7D4D-4285-9B08-A464F4A67178 @default.
- Q93155465 P921 Q93155465-F354A67B-6688-4769-ABFD-D8F1C7E96CE8 @default.
- Q93155465 P356 14737140.2019.1609355 @default.
- Q93155465 P698 30995130 @default.
- Q93155465 P1433 Q2999044 @default.
- Q93155465 P1476 "Chronic tyrosine kinase inhibitor (TKI) use in metastatic renal cell carcinoma (mRCC): can this lead to the adverse effect of hypogonadism?" @default.
- Q93155465 P2093 "Abhishek Kumar" @default.
- Q93155465 P2093 "Ankit Jain" @default.
- Q93155465 P2093 "Emilio Porfiri" @default.
- Q93155465 P2093 "Hiten R H Patel" @default.
- Q93155465 P2093 "Mehran Afshar" @default.
- Q93155465 P2093 "Nicholas D James" @default.
- Q93155465 P2093 "Prashant Patel" @default.
- Q93155465 P304 "529-532" @default.
- Q93155465 P31 Q13442814 @default.
- Q93155465 P356 "10.1080/14737140.2019.1609355" @default.
- Q93155465 P433 "6" @default.
- Q93155465 P478 "19" @default.
- Q93155465 P577 "2019-05-02T00:00:00Z" @default.
- Q93155465 P698 "30995130" @default.
- Q93155465 P921 Q1164529 @default.
- Q93155465 P921 Q19000948 @default.
- Q93155465 P921 Q938107 @default.